Day: January 4, 2019

Neon Therapeutics Provides Business Update and Outlook for 2019

From Startup Neon Therapeutics Link to Full Article: CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today provided a business update and outlook for 2019. “We have an exciting year ahead of us in 2019, with multiple data

Genevant President & CEO Dr. Bo Rode Hansen to Present at Biotech Showcase 2019

From Startup Genevant Link to Full Article: https://genevant.com/genevant-president-ceo-dr-bo-rode-hansen-to-present-at-biotech-showcase-2019/ BOSTON, MASSACHUSETTS; BURNABY, CANADA; and BASEL, SWITZERLAND – January 3, 2019 – Genevant Sciences, a leading biopharmaceutical company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics across multiple modalities, announced today that its President & CEO

BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2381958 NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President and Chief Executive Officer, will provide a corporate overview

90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study

From Startup Heron Therapeutics Link to Full Article: https://herontherapeutics.gcs-web.com/news-releases/news-release-details/90-patients-remain-opioid-free-when-htx-011-given-over-counter SAN DIEGO, Jan. 3, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a

Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 Catalysts

From Startup Synlogic Tx Link to Full Article: – Presentation of topline clinical data from studies of Synthetic Biotic™ medicines, SYNB1020 and SYNB1618, in patients expected mid-2019 – – Investigational New Drug (IND) application for SYNB1891, Synlogic’s first immuno-oncology program, expected in 2H2019 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 3, 2019– Synlogic,